Uses Lactobacillus-Derived Extracellular Vesicles as Natural Antiviral Agents
These Lactobacillus-derived extracellular vesicles (EVs) activate antiviral pathways and modulate host immunity to treat avian flu. Bacterial extracellular vesicles are increasingly at the forefront of research as mediators of host-microbe interactions. EVs are ubiquitously produced in all domains of life and can have constant interactions with a host.
Avian influenza is a highly contagious viral disease affecting both wild and domesticated birds, with certain strains capable of crossing into humans. The global avian influenza vaccines market stood at USD 1.24 billion in 2025 and is projected to reach USD 2.65 billion by 2034 , reflecting the urgent demand for new, dynamic antiviral strategies. According to the World Health Organization, avian flu outbreaks pose serious threats to poultry production and public health worldwide. In recent years, there has been significant interest in probiotics and their secreted vesicles as natural immunomodulators that enhance antiviral defenses.
Researchers at the University of Florida have identified an approach using Lactobacillus-derived extracellular vesicles. These vesicles enhance the host's innate defense mechanisms by robustly activating the OAS pathway and stimulating antiviral responses in chicken-derived cell lines. This highlights their potential as a biotherapeutic approach to complement vaccines and reduce the burden of diseases caused by RNA viruses, such as avian influenza.
Application
Harnesses probiotic vesicles to activate host antiviral pathways to treat avian flu
Advantages
- Activates antiviral pathways (OAS and interferons), reducing RNA viral replication in a host
- Delivers bioactive molecules, modulating host innate immunity and decreasing cytokine-induced apoptosis
- Induces the OAS pathway, enhancing antiviral responses and lowering the incidence and severity of viral outbreaks
Technology
Lactobacillus-derived extracellular vesicles (EVs) are promising for antiviral therapy, including against avian flu. However, their practical application is hindered by limited knowledge of how EV-delivered bioactive molecules modulate host immunity and activate antiviral pathways. Researchers at the University of Florida have demonstrated that these EVs induce strong OAS pathway activation and generate antiviral responses in chicken-derived macrophages. This platform highlights the potential of EVs to reduce viral replication, enhance immune regulation, and advance therapeutic strategies for the treatment of avian influenza.
Brochure
